Canaccord downgraded Intra-Cellular (ITCI) to Hold from Buy with a price target of $132, up from $119, after Johnson & Johnson (JNJ) agreed to acquire all of the company’s outstanding shares for $132 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond
- Reviva Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
- Intra-Cellular downgraded to Sector Perform from Outperform at RBC Capital
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- Roth MKM biotech analyst holds an analyst/industry conference call